Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor with or without Empagliflozin in NASH and Type 2 Diabetes Mellitus
2021-005057-87Phase 2Completed
- Sponsor
- Inventiva
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM) comparing Lanifibranor monotherapy, Lanifibranor + Empagliflozin (Jardiance) and Placebo (3 arms). Primary endpoint: Primary efficacy endpoint. Started Feb 2022; status: completed.
02
Drugs
lanifibranorempagliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-005057-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005057-87.